BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Marketing

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

Avecho and Sandoz Ink 10-Year Deal for Australia’s First Pharmaceutical CBD Capsule for Insomnia

Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia...

March 04, 2025 | News

C2 PHARMA Secures CEP Approval for Oxybuprocaine Hydrochloride, Expanding Global Market Access

C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the appro...

January 29, 2025 | News

Akkodis Acquires Raland Compliance Partners to Expand Life Sciences Regulatory and Quality Expertise

Akkodis, a global digital engineering company and Smart Industry leader, today announced that it has acquired US-based Raland Compliance Partners, LLC (Ral...

January 24, 2025 | News

Akeso Inc. Receives Milestone Payment from Sichuan Kelun for PD-L1 Antibody Tagitanlimab After China’s Regulatory Approval

Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their coll...

January 23, 2025 | News

ImmunityBio Advances Marketing Authorization Applications for BCG-Unresponsive NMIBC CIS in Europe and the UK

Marketing authorization application for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in situ (CIS) submitted to Europ...

January 16, 2025 | News

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctoco...

January 02, 2025 | News

Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education

Ngee Ann Polytechnic’s School of Life Sciences and Chemical Technology (LSCT) is proud to announce a groundbreaking partnership with Merck Singapore ...

December 03, 2024 | News

BeiGene Rebrands as BeOne Medicines, Embracing a United Vision to Defeat Cancer Globally

The new name reflects a bold vision to eradicate cancer by leveraging the transformative power of global collaboration and multi-sectoral partn...

November 18, 2024 | News

Eisai Expands Direct Presence in Saudi Arabia with New Pharmaceutical Sales Subsidiary

Eisai announced the commencement of full-scale operations at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a wholly-o...

October 02, 2024 | News

Zuellig Pharma Secures Exclusive Distribution Agreement with Regeneron to Launch Libtayo® in South Korea and Taiwan

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owne...

August 28, 2024 | News

CBC Group and Hasten Biopharmaceutical Acquire Asset Rights of 14 Branded Products from Celltrion in Major Pan-Asia Expansion

CBC Group (“CBC”), Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its control...

July 01, 2024 | News

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Advanced Cancer Profiling Services to Middle East and Africa

Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, h...

June 24, 2024 | News

Stay Connected